Financial Data and Key Metrics Changes - The company reported total sales of $1.57 billion for Q4 2025, reflecting an 11.6% year-over-year growth, and a full-year growth of 10.7% [5][22] - Adjusted earnings per share (EPS) for Q4 was $0.58, while GAAP EPS was $0.11, impacted by one-time charges related to the JenaValve acquisition and litigation expenses [22][24] - The adjusted gross profit margin for Q4 was 78.3%, slightly down from 79.0% in the previous year, attributed to increased manufacturing expenses [23][24] Business Line Data and Key Metrics Changes - TAVR global sales reached $1.16 billion in Q4, increasing by 10.6% year-over-year, with procedural growth in the high single digits [10][11] - TMTT sales grew over 40% to $156 million in Q4, with full-year sales exceeding $1 billion [16] - Surgical product group sales for Q4 were $254 million, a 2% increase year-over-year, with full-year sales surpassing $1 billion [18] Market Data and Key Metrics Changes - The U.S. and international markets showed comparable TAVR procedural growth, with stable average pricing and competitive positioning globally [11][15] - In Europe, TAVR results reflected healthy underlying procedural growth, supported by updated clinical guidelines [14][15] Company Strategy and Development Direction - The company focuses solely on Structural Heart, aiming to solve complex patient needs and innovate within the market [5][9] - Plans to pioneer new therapies and expand indications over the next three years, with a long-term sales growth expectation of 10% annually [10][29] - The company is investing in patient access initiatives and partnerships, such as with the American Heart Association, to enhance treatment awareness [14][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2026 sales growth guidance of 8%-10% and EPS guidance of $2.90-$3.05, citing strong Q4 performance as a foundation [22][27] - The company anticipates a potential tailwind from an updated national coverage determination for TAVR later in the year [8][50] - Management highlighted the importance of timely and equitable access to care for patients, particularly in light of new clinical guidelines [12][76] Other Important Information - The company maintains a strong balance sheet with approximately $3 billion in cash and cash equivalents as of December 31 [25] - The company has about $2 billion remaining under its share repurchase authorization, with plans to continue repurchasing shares opportunistically [26][70] Q&A Session Summary Question: Insights on TAVR growth and market share - Management noted that TAVR grew 10.6% year-over-year, driven by compelling clinical evidence and a renewed focus on proactive treatment [34][35] Question: Increased spending on market access initiatives - The company increased SG&A spending by $112 million year-over-year to support strategic investments in patient access and education [39][40] Question: TAVR NCD and its potential impact - Management indicated that the reopening of the TAVR NCD process is crucial for improving patient access, with a draft expected around June [50][51] Question: LAA market opportunity and differentiation - The company sees significant unmet needs in the LAA market and plans to introduce differentiated technology to address these needs [52][56] Question: Comments on guideline changes in Europe - Management highlighted the shift in European guidelines towards proactive disease management, which is expected to drive procedural growth [76][77]

Financial Data and Key Metrics Changes - The company reported a strong fourth quarter growth of 11.6% and a full year growth of 10.7% for 2025, driven by a differentiated strategy focused on structural heart solutions [4][5] - Total sales for Q4 reached $1.57 billion, with adjusted earnings per share (EPS) of $0.58, although this was lower than expected due to increased spending on patient access initiatives and a higher tax rate [18][19] - The adjusted gross profit margin for Q4 was 78.3%, slightly down from 79.0% year-over-year, attributed to higher manufacturing expenses related to new therapies [19][20] Business Line Data and Key Metrics Changes - TAVR global sales in Q4 were $1.16 billion, increasing by 10.6% year-over-year, reflecting strong procedural growth and stable pricing [8][9] - TMTT sales grew over 40% to $156 million in Q4, with full year sales exceeding $1 billion, driven by the adoption of PASCAL and EVOQUE therapies [13][14] - Surgical product group sales for Q4 were $254 million, a 2% increase year-over-year, with full year sales surpassing $1 billion [15][16] Market Data and Key Metrics Changes - The U.S. market saw a significant increase in TAVR procedures, driven by a shift towards proactive disease management and the introduction of new clinical guidelines [10][11] - In Europe, TAVR procedure growth was healthy, supported by updated guidelines that emphasize proactive management of severe aortic stenosis [11][12] - The company noted modest year-over-year share improvement in several key countries, strengthening its leadership position following a competitor's exit [12] Company Strategy and Development Direction - The company is focused on pioneering new therapies and expanding indications to address unmet patient needs, with a long-term sales growth expectation of 10% annually [7][8] - The strategy emphasizes the importance of generating world-class clinical evidence to differentiate its valve technologies and maintain clinician preference [7] - The company plans to invest in the development of safe and effective valve therapies, with a commitment to addressing structural heart diseases [7][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2026 sales growth guidance of 8%-10% and EPS guidance of $2.90-$3.05, citing strong momentum entering the new year [23][25] - The management highlighted the importance of the Early TAVR trial and long-term data in reinforcing confidence among physicians and patients [5][10] - The company anticipates a potential tailwind from an updated national coverage determination for TAVR later in the year, which could enhance patient access [10][46] Other Important Information - The company has approximately $3 billion in cash and cash equivalents and $2 billion remaining under its share repurchase authorization [22][66] - Increased SG&A spending in Q4 was intentional to support strategic investments in patient access and education initiatives [20][36] Q&A Session Summary Question: Insights on TAVR growth and market share - Management noted that TAVR growth of 10.6% was supported by compelling clinical evidence and a renewed focus on proactive treatment, with share gains attributed to the exit of a competitor [28][30][31] Question: Increased spending on market access - The increase in SG&A spending was planned to support strategic initiatives, with expectations for moderated growth in 2026 [34][36] Question: TAVR NCD and its impact - Management indicated that the reopening of the NCD process is crucial for improving patient access, with potential impacts expected more significantly in 2027 and beyond [46][47] Question: LAA market opportunity - The company sees significant unmet needs in the LAA market and plans to enter this space with differentiated technology [49][51] Question: M3 uptake and European guidelines - The SAPIEN M3 launch is progressing as expected, with positive outcomes reported, while European guidelines are shifting towards proactive management of mitral and tricuspid diseases [70][73]

Financial Data and Key Metrics Changes - The company reported total sales of $1.57 billion for Q4 2025, reflecting an 11.6% year-over-year growth, and a full-year growth of 10.7% [4][19] - Adjusted earnings per share (EPS) for Q4 was $0.58, while GAAP EPS was $0.11, impacted by one-time charges related to the GeneValve acquisition and litigation expenses [19][20] - The adjusted gross profit margin for Q4 was 78.3%, slightly down from 79.0% in the previous year, attributed to increased manufacturing expenses [20][21] Business Line Data and Key Metrics Changes - TAVR global sales reached $1.16 billion in Q4, growing 10.6% year-over-year, with procedural growth in the high single digits [9][10] - TMTT sales grew over 40% to $156 million in Q4, with full-year sales exceeding $1 billion [15] - Surgical product group sales were $254 million in Q4, a 2% increase year-over-year, with full-year sales surpassing $1 billion [17] Market Data and Key Metrics Changes - The U.S. market showed strong procedural growth for TAVR, driven by increased urgency in treating severe aortic stenosis patients [11][52] - In Europe, updated guidelines are reshaping clinical discussions and expanding the patient population eligible for TAVR [12][50] - The company noted modest year-over-year share improvement in several key countries, strengthening its leadership position [13] Company Strategy and Development Direction - The company is focused on structural heart solutions, aiming for 8%-10% sales growth in 2026 and a long-term average annual sales growth of 10% [6][9] - Plans include pioneering new therapies, launching next-generation technologies, and expanding indications to treat more patients [8][9] - The company is investing in patient access initiatives and partnerships, such as with the American Heart Association, to improve care for heart valve disease [12][30] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in meeting 2026 sales and EPS guidance, citing strong Q4 performance and growth catalysts [25][26] - The company anticipates a potential tailwind from an updated national coverage determination for TAVR later in the year [7][36] - Management highlighted the importance of lifetime management in TAVR, emphasizing the shift towards earlier treatment of aortic stenosis [41][42] Other Important Information - The company maintains a strong balance sheet with approximately $3 billion in cash and cash equivalents [23] - There is approximately $2 billion remaining under the share repurchase authorization, with plans to continue repurchasing shares opportunistically [24][47] Q&A Session Summary Question: Insights on TAVR growth and market share - Management noted strong TAVR growth of 10.6% year-over-year, driven by compelling clinical evidence and a renewed focus on TAVR as a treatment option [28] Question: Increased spending on market access initiatives - The company increased SG&A spending by $112 million year-over-year to support strategic investments in patient access and education [30] Question: Impact of distributor inventory adjustments - The company clarified that the distributor adjustments in Q4 were specific to one country and did not significantly impact overall sales [55]